TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients affected by COPD~Exclusion Criteria:~* other diseases other than COPD

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active osteopathic treatment (OMT+PR) (Type: ACTIVE_COMPARATOR): The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
- SOT + PR (Type: SHAM_COMPARATOR): Sham osteopathic treatment (manipulation)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Type 2 diabetes - Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s) Exclusion Criteria: - Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant females at least 6 years of age who had been diagnosed and treated for recurrent, non-infectious uveitis affecting the posterior segment of one or both eyes for at least 1 year prior to the start of the study, and had 'quiet' eyes at surgery~Exclusion Criteria:~* Coexisting medical or ocular conditions that would interfere with the study results

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluocinolone acetonide 0.59mg (Type: EXPERIMENTAL): Fluocinolone acetonide ocular implant 0.59mg
- Fluocinolone acetonide 2.1mg (Type: EXPERIMENTAL): Fluocinolone acetonide ocular implant 2.1mg
- No intervention (Type: NO_INTERVENTION): Fellow eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* We will include stage 3a, 3b and 4 CKD patients, aged 18 years or over with normal serum phosphate levels (≤ 4.6 mg/dl)~Exclusion Criteria:~* Patients with rapidly advancing renal failure who thus might develop hyperphosphatemia or end stage renal disease requiring initiation of dialysis during the study period~* Patients expected to require dialysis initiation within the follow up period~* Patients with hyperphosphatemia \> 4.6 mg/dl~* Patients with any previous or current treatment with phosphate binders or active vitamin D (doxercalciferol or calcitriol)~* Malnutrition, defined as a serum albumin \< 3.0 mg/dl~* Patients with liver disease (ALT or AST \> 100 U/L) or cholestasis (direct bilirubin \> 1.0 mg/dl) because this can limit their ability to absorb fat soluble vitamins such as vitamin D~* Anemia, defined as a hematocrit \< 27% at the screening visit~* Medical conditions impacting Pi metabolism-primary hyper- or hypoparathyroidism; Patients with previous subtotal parathyroidectomy; gastrointestinal malabsorption disorders such as Crohn's Disease, ulcerative colitis, celiac disease, or severe liver dysfunction;~* Patients with outpatient counseling by a renal nutritionist within the previous 6 months~* Hospitalization within the previous 4 weeks~* Pregnancy or breastfeeding mothers~* Patients unable to independently provide written informed consent - prisoners, mentally incompetent, minors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 900 mg Phosphate Diet-LC (Type: ACTIVE_COMPARATOR): dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
- Ad Libitum Diet-LC (Type: ACTIVE_COMPARATOR): no dietary intervention + phosphorus binder (Lanthanum Carbonate)
- 900 mg Phosphate Diet-LC Placebo (Type: ACTIVE_COMPARATOR): dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
- Ad Libitum Diet-LC Placebo (Type: PLACEBO_COMPARATOR): no dietary intervention + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* anyone not excluded and consenting~Exclusion Criteria:~* contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin~* anyone seriously ill~* currently taking antimalarial medicines~* allergy to artemisinin drugs~* pregnant women in first trimester~* children under 3 months of age~* reported heart condition

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Reactive Focal Drug Administration (Type: EXPERIMENTAL): This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
- Reactive Focal Test and Treat (Type: NO_INTERVENTION): This is the current standard of care in Southern Province and is described by a reactive response to passively detected index case of malaria. The reactive response consists of testing all individuals within a defined radius of each RDT-confirmed incident malaria case with an RDT and treating all positive individuals with artemether-lumefantrine (AL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lamazym Aftercare Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* the subject must have participated in previous Lamazym-trials: phase 2b: 2011-004355-40 or phase 3: 2012-000979-17~* Subject or subjects legally authorized guardian(s) must provide signed, informed consent prior to performing any trial-related activities~* The subject and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~* Presence of known clinically significant cardiovascular, hepatic, pulmonary, or renal disease or other medical conditions that, in the opinion of the Investigator, would preclude participation in the trial~* Any other medical condition or serious intercurrent illness, or extenuating circumstances that, in the opinion of the Investigator, would preclude participation in the trial~* Pregnancy. Pregnant woman is excluded. Before start fot he treatment the investigators will for women of childbearing potential perform a pregnancy test and decide whether or not there is a need for contraception~* Psychosis; any psychotic disease, also in remission, is an exclusion criteria~* Planned major surgery that, in the opinion of the Investigator, would preclude participation in the trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lamazym (Type: EXPERIMENTAL): 1 mg Lamazym/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Dexmedetomidine on the Heart Beat During Elective Surgery in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ASA Physical Status I-II~* Age 3 to 10yrs~* Elective surgical procedure requiring general anesthesia~* Use of dexmedetomidine acceptable to the staff anesthesiologist~* Un-premedicated~* Ability to read and understand English (parent/legal guardian(s) and child)~Exclusion Criteria:~* Long QT syndrome (LQTS)~* Cardiac disease or rhythm abnormalities~* Family history of LQTS or abnormal cardiac conduction~* Currently taking medications known to prolong QT~* Currently taking medications known to predispose to hypokalemia~* Known hypersensitivity to dexmedetomidine or other study medication~* Weight \< 5th centile or \> 95th centile for age~* Previously diagnosed hypokalemia~* Impaired renal or liver function~* Pre-operative anxiety requiring sedatives or opioids~* Refusal to participate

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine 0.25mcg/kg (Type: EXPERIMENTAL): 0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
- Dexmedetomidine 0.5mcg/kg (Type: EXPERIMENTAL): 0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
- Dexmedetomidine 0.75mcg/kg (Type: EXPERIMENTAL): 0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
- Saline bolus (Type: SHAM_COMPARATOR): 10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects, \> 40 years of age~2. Clinical diagnosis of moderate to severe COPD as defined by the GOLD criteria:~   Post-bronchodilator FEV1/FVC \< 70% Post-bronchodilator FEV1 \< 70% predicted~3. Cigarette consumption of 10 pack-years or more. Patients may be active smokers.~4. The presence of chronic cough and sputum production~5. Willingness to make return visits and telephone availability for the study duration~Exclusion Criteria:~1. A diagnosis of asthma as established by the study investigator on the basis of the recent American Thoracic Society/European Respiratory Society guidelines~2. Clinically significant bronchiectasis~3. Oxygen use \>12 hours/day~4. Known sensitivity to roflumilast~5. Use of other methylxanthines within 1 month (theophylline)~6. Changes to current maintenance COPD therapy within one month~7. Pregnancy~8. An acute illness requiring antibiotics and/or corticosteroids within the month prior to enrolment.~9. Immunosuppression~   1. HIV~  2. Solid organ transplant~  3. Active malignancy~  4. Systemic corticosteroid use ≥ prednisone 20mg / day~  5. Other immunosuppressants~10. Terminal illness defined as anticipated survival \<12 months~11. Severe comorbidities including uncontrolled angina, congestive heart failure, end-stage renal disease, liver failure, or other conditions that would preclude the patient from safely completing the required tests or the study.~    -

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
- Daliresp (Type: ACTIVE_COMPARATOR): The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the diagnostic criteria for chronic kidney disease, defined as a glomerular filtration rate (GFR) more than or equal to 15 mL/min per 1.73 m2 and less than 60 mL/min per 1.73 m2 (Stages 3 and 4) as calculated by the central laboratory~* Require support of an erythropoietin receptor agonist~Exclusion Criteria:~* Uncontrolled hypertension~* Serum ferritin level less than 50 ng/mL~* Serum iron overload~* Severe congestive heart failure~* Active infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TIW: Epoetin alfa 3 injections Weekly/Once Weekly (Type: EXPERIMENTAL): Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
- QW: Epoetin alfa once weekly (Type: EXPERIMENTAL): Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
- Q2W: Epoetin alfa once every two weeks (Type: EXPERIMENTAL): Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Carcinoma of unknown primary site confirmed by biopsy~* Measurable disease~* ECOG performance status must be 0-1~* Adequate bone marrow, liver and kidney~* Understand the nature of this study and give written informed consent.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age\< 18 years~* May not have received EGFR inhibitors~* History of acute myocardial infarction within 6 months~* Clinically significant cardiovascular disease~* Moderate to severe peripheral vascular disease.~* History of stroke within 6 months~* History of abdominal fistula, perforation, or abscess within 6 months~* Active concurrent infections~* Serious underlying medical conditions~* Active brain metastases~* Women who are pregnant or lactating.~* PEG or G-tube~* Proteinuria~* Any nonhealing wound, ulcer, or bone fracture.~* Any clinical evidence or history of bleeding, clotting or coagulopathy~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age more than or equal to 18 years at the time of signing informed consent~* Body mass index (BMI) more than or equal to 30 kg/m\^2 or more than or equal to 27 kg/m\^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease~* History of at least one self-reported unsuccessful dietary effort to lose body weight~Exclusion criteria:~* HbA1c more than or equal to 48 mmol/mol (6.5%) as measured by the central laboratory at screening~* A self-reported change in body weight more than 5 kg (11 lbs) within 90 days before screening irrespective of medical records

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Participants will receive semaglutide 2.4 mg during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo (semaglutide) during 104-week treatment period in addition to a reduced-calorie diet and increased physical activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prepubertal children with GHD (either isolated or as part of a multiple pituitary hormone deficiency) in Tanner stage 1 (Tanner 1982) aged:~  * Boys: 3-12 years, inclusive~ * Girls: 3-11 years, inclusive~* Impaired height (HT) defined as at least 2.0 standard deviations (SD) below the mean height for chronological age and sex (HT SDS ≤ -2.0) according to the 2000 CDC Growth Charts for the United States Methods and Development, available at http://www.cdc.gov/growthcharts/~* Diagnosis of GHD confirmed by 2 different GH stimulation tests, defined as a peak GH level of ≤10 ng/mL, determined with a validated assay~* Bone age (BA) at least 6 months less than chronological age~* Baseline IGF-1 level of at least 1 SD below the mean IGF-1 level standardized for age and sex (IGF-1 SDS ≤-1)~* Written, signed informed consent of the parent(s) or legal guardian(s) of the subject and written assent of the subject (if the subject is able to read, understand, and sign)~Exclusion Criteria:~* Children with a body weight below 12 kg~* Prior exposure to recombinant hGH or IGF-1 therapy~* Children with past or present intracranial tumor growth as confirmed by a sellar MRI scan (with contrast) at Screening (MRI results from up to 6 months prior to Screening may be accepted)~* Children with psychosocial dwarfism~* Children with idiopathic short stature~* History or presence of malignant disease; any evidence of present tumor growth~* Closed epiphyses~* Major medical conditions and/or presence of contraindication to hGH treatment~* Participation in any other trial of an investigational agent within 3 months prior to Screening

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- TransCon hGH (Type: EXPERIMENTAL): Once weekly subcutaneous injection of TransCon hGH
- human growth hormone (Genotropin) (Type: ACTIVE_COMPARATOR): Once daily subcutaneous injection of Genotropin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete